Aethlon Medical, Inc. (AEMD)
| Market Cap | 5.46M |
| Revenue (ttm) | 574,245 |
| Net Income (ttm) | -11.63M |
| Shares Out | 2.49M |
| EPS (ttm) | -4.92 |
| PE Ratio | n/a |
| Forward PE | 0.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,094 |
| Open | 2.20 |
| Previous Close | 2.18 |
| Day's Range | 2.07 - 2.22 |
| 52-Week Range | 1.40 - 8.70 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+950.23%) |
| Earnings Date | Feb 12, 2024 |
About AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California. [Read more]
Financial Performance
In 2022, AEMD's revenue was $574,245, an increase of 95.21% compared to the previous year's $294,165. Losses were -$12.03 million, 15.5% more than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AEMD stock is "Strong Buy" and the 12-month stock price forecast is $23.0.
News
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat c...
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A.
SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, t...
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and fo...
Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology
SAN DIEGO , Oct. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and f...
Aethlon Announces Reverse Stock Split
SAN DIEGO , Oct. 4, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to...
Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, t...
Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Aug. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat c...
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023
SAN DIEGO , Aug. 3, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, to...
Aethlon Medical Signs Collaboration Agreement with 34 Lives to Evaluate the Ability of the Hemopurifier® to Expand the Utility of Unused, Donated Kidneys for Transplant
Proof-of-Concept Studies to Support the Use of the Hemopurifier in the Ex Vivo Organ Perfusion Circuit SAN DIEGO, July 24, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therape...
Aethlon Medical Appoints Medical Device and Biomedical Executive, Nicolas Gikakis, to its Board of Directors
SAN DIEGO , July 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to...
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
Conference Call to be Held Today at 4:30pm ET SAN DIEGO , June 28, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat canc...
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
SAN DIEGO , June 22, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, t...
Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation
Research to Confirm the Hemopurifier's Ability to Remove Harmful Viruses and Exosomes From Harvested Organs SAN DIEGO , June 21, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical th...
Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest
SAN DIEGO , June 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectiou...
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
SAN DIEGO , June 1, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious...
Aethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India
SAN DIEGO , May 22, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious...
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Feb. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectiou...
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023
SAN DIEGO , Feb. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that i...
Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
Presentation on Thursday, February 2nd, 2023 at 10:00 AM ET SAN DIEGO , Jan. 31, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and ...
Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
SAN DIEGO , Jan. 30, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that i...
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Nov. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectiou...
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022
SAN DIEGO , Nov. 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that i...
Aethlon Medical to Present at Two Investor Conferences in September
SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectiou...
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious...
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022
SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that i...